Clinical trial
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
NCT01629667 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
- Lead sponsor
- MedImmune LLC
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- October 31, 2012
- Completion date
- January 31, 2016
- Enrollment
- 409 (actual)
- Sites
- 45
Conditions
As the registry lists them; a condition with its own page is linked.